A 12-month, open-label, flexible-dosage study to evaluate the safety and efficacy of Gabitril treatment (up to 16 mg/day) in adults with generalized anxiety disorder [GAD]

Trial Profile

A 12-month, open-label, flexible-dosage study to evaluate the safety and efficacy of Gabitril treatment (up to 16 mg/day) in adults with generalized anxiety disorder [GAD]

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2007

At a glance

  • Drugs Tiagabine (Primary)
  • Indications Generalised anxiety disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Cephalon
  • Most Recent Events

    • 07 Sep 2007 Status changed from in progress to completed.
    • 05 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top